Duke University School of Medicine
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Duke University School of Medicine
Tech Transfer Roundup: NCI Licenses Leukemia, Brain Cancer Candidates To Vor, Connectyx
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
Tech Transfer Roundup: Inside The Law That Transformed The Research Landscape
The Bayh-Dole act of 1980 facilitated deal-making between private-sector firms and research institutions, largely seeding the US biotech industry. Plus, an overview of the latest tech transfer deals.
Tech Transfer Roundup: Be Cool Therapeutics Sees Potential In Mimicking Hibernation
Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.
Tech Transfer Roundup: OncoSec Will Investigate CAR-T In Breast Cancer With Dana-Farber
Building on research by Dana-Farber professor Wayne Marasco, the partners are backing a bispecific approach to CAR-Ts in solid tumors. Seelos licenses a Parkinson’s gene therapy candidate from Duke.
- Academic and Research Institutions
- Other Names / Subsidiaries
- Duke University Medical Center
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.